Bristol Myers Squibb Company $BMY Shares Sold by Skylands Capital LLC

Key Points

• Skylands Capital trimmed its stake in Bristol Myers Squibb by 11.4% (sold 18,400 shares) leaving 142,480 shares worth $7.60M, and EVP David V. Elkins sold 30,000 shares at an average $61.67 (≈$1.85M), reducing his ownership by 15.85%.
• BMS reported a quarterly EPS miss of $1.26 versus $1.65 expected while revenue of $12.50B slightly beat estimates, and the company set FY2026 guidance of $6.05–$6.35 EPS (analysts average ~6.28).
• The board declared a quarterly dividend of $0.63 per share (annualized $2.52), representing a 4.4% yield and a payout ratio of about 73%.

Skylands Capital LLC lowered its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 142,480 shares of the biopharmaceutical company's stock after selling 18,400 shares during the quarter. Skylands Capital LLC's holdings in Bristol Myers Squibb were worth $7,596,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of BMY. Brighton Jones LLC lifted its holdings in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC lifted its holdings in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock worth $346,000 after purchasing an additional 2,786 shares during the period. United Bank lifted its holdings in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock worth $1,164,000 after purchasing an additional 3,277 shares during the period. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb in the second quarter worth about $221,000. Finally, Nebula Research & Development LLC acquired a new stake in Bristol Myers Squibb in the second quarter worth about $405,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

BMY stock opened at $57.86 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The firm has a market capitalization of $118.13 billion, a PE ratio of 16.77, a P/E/G ratio of 0.17 and a beta of 0.27. The firm has a 50-day moving average of $59.63 and a two-hundred day moving average of $54.31.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion for the quarter, compared to analysts' expectations of $12.24 billion. During the same period in the prior year, the company posted $1.67 earnings per share. Bristol Myers Squibb's quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.28 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio is currently 73.04%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald upped their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a report on Wednesday, April 8th. Guggenheim reissued a "buy" rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Wells Fargo & Company reissued an "outperform" rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Weiss Ratings reissued a "hold (c)" rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Finally, UBS Group reissued a "buy" rating and issued a $70.00 price target on shares of Bristol Myers Squibb in a report on Friday, March 6th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.